Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: A matched pair analysis

P. Duggan, K. Booth, A. Chaudhry, D. Stewart, J. D. Ruether, S. Glück, D. Morris, C. B. Brown, B. Herbut, M. Coppes, R. Anderson, J. Wolff, M. Egeler, S. Desai, A. R. Turner, L. Larratt, E. Gyonyor, J. A. Russell

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Fifty-seven patients receiving unrelated donor (UD) BMT were matched for disease and stage with 57 recipients of genotypically matched related donor (MRD) BMT. All UD recipients were matched serologically for A and B and by high resolution for DR and DQ antigens. All patients received CsA and 'short course' methotrexate with folinic acid. Unrelated donor BMT patients also received thymoglobulin 4.5 mg/kg (6 mg/kg if <30 kg) in divided doses over 3 days pretransplant. For UD and RD BMT, respectively, incidence of acute GVHD grade II-IV was 19 ± 6% vs 36 ± 8%, grade III-IV 10 ± 6% vs 18 ± 7%, chronic GVHD 44 ± 8% vs 51 ± 8%, non-relapse mortality 15 ± 5% vs 8 ± 4% at 100 days, 28 ± 8% vs 36 ± 7% at 3 years. At 3 years, relapse was 45 ± 7% vs 42 ± 7%, and disease-free survival 39 ± 7% vs 37 ± 7%. None of these differences are significant. Three-year overall survival was identical at 42 ± 7%. For 29 patients with low/intermediate risk leukemia, disease-free survival was 68 ± 10% after UD BMT vs 59 ± 9% for RD BMT recipients (P = NS). Corresponding figures for high risk patients were 14 ± 7% and 21 ± 8%, respectively. We conclude that UD BMT recipients matched as above and given pretransplant ATG have similar outcomes to recipients of MRD BMT using conventional drug prophylaxis. Unrelated donor BMT should be considered in any circumstance where MRD BMT is routine.

Original languageEnglish
Pages (from-to)681-686
Number of pages6
JournalBone Marrow Transplantation
Volume30
Issue number10
DOIs
StatePublished - Nov 1 2002
Externally publishedYes

Fingerprint

Matched-Pair Analysis
Unrelated Donors
Antilymphocyte Serum
Siblings
Tissue Donors
Disease-Free Survival
Leucovorin
Methotrexate
Leukemia
Antigens
Recurrence
Survival
Mortality
Incidence
Pharmaceutical Preparations

Keywords

  • Antithymocyte globulin
  • Bone marrow transplant
  • Graft-versus-host disease
  • Unrelated

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT : A matched pair analysis. / Duggan, P.; Booth, K.; Chaudhry, A.; Stewart, D.; Ruether, J. D.; Glück, S.; Morris, D.; Brown, C. B.; Herbut, B.; Coppes, M.; Anderson, R.; Wolff, J.; Egeler, M.; Desai, S.; Turner, A. R.; Larratt, L.; Gyonyor, E.; Russell, J. A.

In: Bone Marrow Transplantation, Vol. 30, No. 10, 01.11.2002, p. 681-686.

Research output: Contribution to journalArticle

Duggan, P, Booth, K, Chaudhry, A, Stewart, D, Ruether, JD, Glück, S, Morris, D, Brown, CB, Herbut, B, Coppes, M, Anderson, R, Wolff, J, Egeler, M, Desai, S, Turner, AR, Larratt, L, Gyonyor, E & Russell, JA 2002, 'Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: A matched pair analysis', Bone Marrow Transplantation, vol. 30, no. 10, pp. 681-686. https://doi.org/10.1038/sj.bmt.1703674
Duggan, P. ; Booth, K. ; Chaudhry, A. ; Stewart, D. ; Ruether, J. D. ; Glück, S. ; Morris, D. ; Brown, C. B. ; Herbut, B. ; Coppes, M. ; Anderson, R. ; Wolff, J. ; Egeler, M. ; Desai, S. ; Turner, A. R. ; Larratt, L. ; Gyonyor, E. ; Russell, J. A. / Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT : A matched pair analysis. In: Bone Marrow Transplantation. 2002 ; Vol. 30, No. 10. pp. 681-686.
@article{6dd29cbafe4b47cb9c0bd3688109e910,
title = "Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: A matched pair analysis",
abstract = "Fifty-seven patients receiving unrelated donor (UD) BMT were matched for disease and stage with 57 recipients of genotypically matched related donor (MRD) BMT. All UD recipients were matched serologically for A and B and by high resolution for DR and DQ antigens. All patients received CsA and 'short course' methotrexate with folinic acid. Unrelated donor BMT patients also received thymoglobulin 4.5 mg/kg (6 mg/kg if <30 kg) in divided doses over 3 days pretransplant. For UD and RD BMT, respectively, incidence of acute GVHD grade II-IV was 19 ± 6{\%} vs 36 ± 8{\%}, grade III-IV 10 ± 6{\%} vs 18 ± 7{\%}, chronic GVHD 44 ± 8{\%} vs 51 ± 8{\%}, non-relapse mortality 15 ± 5{\%} vs 8 ± 4{\%} at 100 days, 28 ± 8{\%} vs 36 ± 7{\%} at 3 years. At 3 years, relapse was 45 ± 7{\%} vs 42 ± 7{\%}, and disease-free survival 39 ± 7{\%} vs 37 ± 7{\%}. None of these differences are significant. Three-year overall survival was identical at 42 ± 7{\%}. For 29 patients with low/intermediate risk leukemia, disease-free survival was 68 ± 10{\%} after UD BMT vs 59 ± 9{\%} for RD BMT recipients (P = NS). Corresponding figures for high risk patients were 14 ± 7{\%} and 21 ± 8{\%}, respectively. We conclude that UD BMT recipients matched as above and given pretransplant ATG have similar outcomes to recipients of MRD BMT using conventional drug prophylaxis. Unrelated donor BMT should be considered in any circumstance where MRD BMT is routine.",
keywords = "Antithymocyte globulin, Bone marrow transplant, Graft-versus-host disease, Unrelated",
author = "P. Duggan and K. Booth and A. Chaudhry and D. Stewart and Ruether, {J. D.} and S. Gl{\"u}ck and D. Morris and Brown, {C. B.} and B. Herbut and M. Coppes and R. Anderson and J. Wolff and M. Egeler and S. Desai and Turner, {A. R.} and L. Larratt and E. Gyonyor and Russell, {J. A.}",
year = "2002",
month = "11",
day = "1",
doi = "10.1038/sj.bmt.1703674",
language = "English",
volume = "30",
pages = "681--686",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT

T2 - A matched pair analysis

AU - Duggan, P.

AU - Booth, K.

AU - Chaudhry, A.

AU - Stewart, D.

AU - Ruether, J. D.

AU - Glück, S.

AU - Morris, D.

AU - Brown, C. B.

AU - Herbut, B.

AU - Coppes, M.

AU - Anderson, R.

AU - Wolff, J.

AU - Egeler, M.

AU - Desai, S.

AU - Turner, A. R.

AU - Larratt, L.

AU - Gyonyor, E.

AU - Russell, J. A.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Fifty-seven patients receiving unrelated donor (UD) BMT were matched for disease and stage with 57 recipients of genotypically matched related donor (MRD) BMT. All UD recipients were matched serologically for A and B and by high resolution for DR and DQ antigens. All patients received CsA and 'short course' methotrexate with folinic acid. Unrelated donor BMT patients also received thymoglobulin 4.5 mg/kg (6 mg/kg if <30 kg) in divided doses over 3 days pretransplant. For UD and RD BMT, respectively, incidence of acute GVHD grade II-IV was 19 ± 6% vs 36 ± 8%, grade III-IV 10 ± 6% vs 18 ± 7%, chronic GVHD 44 ± 8% vs 51 ± 8%, non-relapse mortality 15 ± 5% vs 8 ± 4% at 100 days, 28 ± 8% vs 36 ± 7% at 3 years. At 3 years, relapse was 45 ± 7% vs 42 ± 7%, and disease-free survival 39 ± 7% vs 37 ± 7%. None of these differences are significant. Three-year overall survival was identical at 42 ± 7%. For 29 patients with low/intermediate risk leukemia, disease-free survival was 68 ± 10% after UD BMT vs 59 ± 9% for RD BMT recipients (P = NS). Corresponding figures for high risk patients were 14 ± 7% and 21 ± 8%, respectively. We conclude that UD BMT recipients matched as above and given pretransplant ATG have similar outcomes to recipients of MRD BMT using conventional drug prophylaxis. Unrelated donor BMT should be considered in any circumstance where MRD BMT is routine.

AB - Fifty-seven patients receiving unrelated donor (UD) BMT were matched for disease and stage with 57 recipients of genotypically matched related donor (MRD) BMT. All UD recipients were matched serologically for A and B and by high resolution for DR and DQ antigens. All patients received CsA and 'short course' methotrexate with folinic acid. Unrelated donor BMT patients also received thymoglobulin 4.5 mg/kg (6 mg/kg if <30 kg) in divided doses over 3 days pretransplant. For UD and RD BMT, respectively, incidence of acute GVHD grade II-IV was 19 ± 6% vs 36 ± 8%, grade III-IV 10 ± 6% vs 18 ± 7%, chronic GVHD 44 ± 8% vs 51 ± 8%, non-relapse mortality 15 ± 5% vs 8 ± 4% at 100 days, 28 ± 8% vs 36 ± 7% at 3 years. At 3 years, relapse was 45 ± 7% vs 42 ± 7%, and disease-free survival 39 ± 7% vs 37 ± 7%. None of these differences are significant. Three-year overall survival was identical at 42 ± 7%. For 29 patients with low/intermediate risk leukemia, disease-free survival was 68 ± 10% after UD BMT vs 59 ± 9% for RD BMT recipients (P = NS). Corresponding figures for high risk patients were 14 ± 7% and 21 ± 8%, respectively. We conclude that UD BMT recipients matched as above and given pretransplant ATG have similar outcomes to recipients of MRD BMT using conventional drug prophylaxis. Unrelated donor BMT should be considered in any circumstance where MRD BMT is routine.

KW - Antithymocyte globulin

KW - Bone marrow transplant

KW - Graft-versus-host disease

KW - Unrelated

UR - http://www.scopus.com/inward/record.url?scp=0036861875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036861875&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703674

DO - 10.1038/sj.bmt.1703674

M3 - Article

C2 - 12420207

AN - SCOPUS:0036861875

VL - 30

SP - 681

EP - 686

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -